Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Hank Payments Achieves Record Growth in its Profitable Auto Channel (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Dianthus Therapeutics Inc DNTH

Healthcare Biotechnology
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to advancing antibody complement therapeutics to treat severe autoimmune diseases. The Company is dedicated to designing and delivering monoclonal antibodies with improved selectivity and potency. The Company has initiated a Phase 2 trial of DNTH103, a potential active C1s inhibitor, in generalized Myasthenia Gravis... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:DNTH)

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

GlobeNewswire 13 days ago

Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference

GlobeNewswire May 8, 2024

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 3, 2024

Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting

GlobeNewswire April 11, 2024

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 5, 2024

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

GlobeNewswire March 21, 2024

Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire March 7, 2024

Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG)

GlobeNewswire February 26, 2024
View More News ››

Opinion & Analysis (NDAQ:DNTH)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:DNTH)

Be the first to post on this bullboard.

Visionstate Corp.

Visionstate Corp.

Visionstate Corp. is a growth-oriented company that invests in the research and development of the Internet of Things, big ...
View More »